Such assistance is increasingly necessary given rising volumes of CCTA scans necessary to assess chest pain—the primary cause of outpatient and ED visits. 

These findings could be beneficial for women with dense breasts, which increase the risk of developing cancer while making it significantly more difficult to detect. 

The FDA clearly sees significant potential in a new multi-protein blood test from Prevencio. The company's goal is to gain full approval and get the test in the hands of emergency departments all over the United States.

For some, the FDA is moving too fast in its drive to adopt generative AI agency-wide. 

The collaboration with Nvidia—a leader in AI solutions—was unveiled Monday during the International Society for Magnetic Resonance in Medicine's annual meeting. 

Healthcare consumers considering the use of large language AI for mental healthcare are apt to shy away from the technology if they feel it might put their privacy at risk. 

The FDA is getting AI-aggressive about speeding up device reviews. Its plan is to unleash generative AI on tedious and repetitive tasks.

Deerfield Management released details on its latest Healthcare Innovations Fund program, promising to finance “promising therapeutics” and “elevating emerging technologies," including artificial intelligence.